Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Zura Bio LimitedNASDAQ: ZURA
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 25.6% from a year ago
Other current assets stood at $1.41M at the end of Q1 FY2026, up 25.6% from a year earlier and down 51.4% from the prior quarter. Over 3 fiscal years it compounded at +148.4% a year.
Context
- Other current assets amounted to 0.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +25.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.9M USD
- Year-over-year change
- +29.3%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.9M | +29.3% |
| FY2024 | 2024-12-31 | 2.25M | +116.6% |
| FY2023 | 2023-12-31 | 1.04M | +447.8% |
| FY2022 | 2022-12-31 | 189.3K | — |
| FY2021 | 2022-03-31 | 0 | — |
Other Current Assets vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 other current assets of $1.41M is the 9th highest of the 11 companies compared; the peer median is $3.13M.
- Its year-over-year change of +25.6% is the 3rd highest of 11, against a peer median of -27.3%.
- Other current assets amounts to 0.6% of total assets for ZURA, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.25B | +6889679.5% | +2.1% | 75.1% | |
| Mar 2026 | $6.81M | -23.1% | — | 2.2% | |
| Mar 2026 | $5.56M | +35.7% | +163.2% | 2.4% | |
| Mar 2026 | $4.16M | -89.2% | -17.0% | 1.7% | |
| Mar 2026 | $3.18M | -34.1% | -8.1% | 1.4% | |
| Mar 2026 | $3.08M | -52.1% | -5.6% | 4.8% | |
| Mar 2026 | $2.96M | +6.2% | — | 1.7% | |
| Mar 2026 | $2.38M | -27.7% | +198.4% | 2.4% | |
ZURAZura Bio Limited | Mar 2026 | $1.41M | +25.6% | +148.4% | 0.6% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $650K | -26.8% | +141.9% | 0.6% |
| Mar 2026 | $25K | -98.0% | +3.0% | 0.0% | |
| Peer median (excluding ZURA) | $3.13M | -27.3% | +2.5% | 1.9% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.